Immunade E. Coli Antibody
“Instead of starting with a health problem and trying to find a solution, why not start with a solution and see what health problems it can solve.”
John Hare, Developer of Hyper-Egg Technology and Immunade
Immunade is a solution looking for a problem. Containing the Antibody against E Coli, it should at minimum be effective against E Coli caused Traveler's Diarrhea. And if effective here, would it not also aid in the elimination of E Coli caused Child Diarrhea in less developed countries. Going further, if E Coli is the first bad bacteria to overgrow during Gut Microbiome Dysbiosis, which has been linked to many health disorders, maybe controlling this overgrowth would prevent or eliminate those health disorders.
And since the make up our Gut Microbiome is only 10 - 30% the same among humans, maybe Immunade will only help 10 - 30% of the population, which could be considered a breakthrough if the problem happened to be a life threatening disease.
With Immunade, we hypothesize that every health disorder is caused by Gut Microbiome Dysbiosis and E Coli is the foremost bad bacteria to overgrow. If we can prevent this overgrowth we can prevent the disorder, at least in 10 - 30% of the population.
Our intention is to start trials with suitable patients for various chronic health disorders including:
IBD; Osteoarthritis and joint pain; Allergies, Asthma. Coeliac; IBS; Cardiovascular Disease; Stress; Thyroid problems; Autoimmune Disorders; Obesity; Anxiety, Depression and Mental Illness; Aging; Alzheimer's; Parkinson's; Multiple Scerlosis.
Clostridium Difficile Antibody
The Super-bug Clostridium Difficile is a gram positive, spore forming bacteria known primarily for causing antibiotic associated diarrhea in patients admitted to hospitals and residents of health care facilities. The rate of incidence and severity of C. diff infections (CDI) has risen, annually affecting between 1 – 3 million people in North America and Europe. In severe cases, symptoms include pseudo membranous colitis, bowel perforation, and death. About 30,000 deaths annually in the USA are linked to CDI (CDC report: January 2015), with over 90% of these being patients 65 years of age or older. CDI is responsible for more deaths than all other intestinal infections combined.
Current medical treatment constitutes the use of certain antibiotics at a cost of between $2,000 and $16,000 per patient. C. Diff however has proven resistant as the current therapy has failed to cure about 25-30% of patients and new strains have evolved with increasing resistance and higher virulence. With aging populations rising in both North America and European countries, increasing placements in acute care and long-term care environments and continued widespread use of antibiotics, Clostridium Difficile Infection presents a growing threat to public health. A new, effective treatment will represent a huge advance in medical science, where the annual health care cost of this disease in the United States alone is estimated at over $3 Billion.
In pursuit of the project goals, we have already accomplished the following:
- Tested the effectiveness of C. Diff antibodies in laboratory studies.
- Tested the effectiveness of C. Diff antibodies in piglets with C. Diff infections.
- Proved effectiveness of antibody therapy in proof of concept clinical studies in patients with C. Diff infections in collaboration with Gastroenterologists from Australia, the United States and Canada and demonstrated positive clinical response.
- Developed appropriate clinical development plan and budget.
- Received approval from Health Canada for commencement of phase 2 clinical trials.
- Initiated contact with clinicians to commence clinical trials.
- Submitted patent applications in the U. S. A., Canada and Europe.